Digital prescription therapeutic company Pear Therapeutics announced Monday it had secured up to $50 million in additional capital from an affiliate of Thimble Point Acquisition Corp., the special purpose acquisition company it plans to merge with in order to trade publicly.
The new investment is adding to the $23 million Thimble Point’s sponsor already committed as part of the private investment...
Pear Therapeutics announced Wednesday that Massachusetts’ Medicaid program plans to cover its digital prescription therapeutics for treating substance and opioid use disorders, reSET and reSET-O.
The decision to cover the digital therapeutics under MassHealth is subject to federal and state approval as well as the availability of funding.
“We applaud MassHealth for their leadership in introducing...
A "refill" of Pear Therapeutics’ reSET-O digital prescription therapeutic for treating opioid use disorder is associated with high levels of abstinence and treatment retention as well as fewer hospital encounters, according to a study published in Hospital Practice.
Most of the study’s authors are current or former Pear employees.
TOP-LINE DATA
Out of a group of 3,817 people who completed a 12-...
Pear Therapeutics' reSET-O, a prescription app for treating opioid use disorder, may lower patients’ health care costs, compared with patients who don’t use the app, according to a study published in the journal Hospital Practice.
“Engagement and continued treatment with reSET-O in patients with OUD treated with buprenorphine is associated with substantial real-world reductions in medical costs...
Digital therapeutic company Pear announced its plans to go public via a $1.6 billion special purpose acquisition company (SPAC) merger with Thimble Point Acquisition Corp.
The new combined company will be called Pear Holdings Corp and traded on Nasdaq. Pear leadership will continue to head up the new combined entity. According to the companies, the combined business includes up to $276 million in...
Digital therapeutics company Pear Therapeutics is looking to integrate digital biomarkers, machine learning algorithms and sensor-based technologies into its platform thanks to new licensing deals and partnerships.
The Boston-based DTx company has inked collaboration deals with Empatica and etectRx, as well as licensing tech from KeyWise.
Specifically, Pear's collaboration with Empatica will...
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer clinical encounters and subsequently decreased medical costs over a six-month period.
The study was funded by Pear, coauthored by a Pear employee and published in the journal Expert Review of...
Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway.
The first, a randomized controlled trial of 1,149 Australian adults with insomnia and depressive symptoms, suggested...
Over the last decade, the addiction and mental health space has becoming increasingly digital – so much so that the first prescription digital therapeutic, Pear’s ReSET, scored FDA clearance nearly three years ago. While more and more players begin to join the so-called "DTx" space, the technology is yet to hit the mainstream radar, but a new coalition is looking to change that.
A list of high-...
Digital therapeutics company Pear Therapeutics has inked a deal with pharmacy benefits manager (PBM) RemedyOne, allowing the latter to offer and administer benefit coverage for the formers’ prescription-addiction-focused therapies reSET and reSET-O to its customers.
Both reSET and reSET-O have FDA clearances. In fact, reSET was the first software-only therapeutic to get the designation. reSET ...
.jpg?itok=boZHWQkf "Young urban businesswoman using smartphone in the office in front of windows overlooking the city")
